ABEO - Abeona Therapeutics Inc.
| Previous Close | 7.52 |
| Open | 7.54 |
| Bid | 7.60 x 800 |
| Ask | 7.63 x 800 |
| Day's Range | 7.36 - 7.64 |
| 52 Week Range | 6.26 - 22.00 |
| Volume | 95,683 |
| Avg. Volume | 416,926 |
| Market Cap | 361.022M |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 25.22 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT
Q4 2018 Abeona Therapeutics Inc Earnings Call
Motley Fool•6 days agoAbeona Therapeutics Inc (ABEO) Q4 2018 Earnings Conference Call Transcript
ABEO earnings call for the period ending December 31, 2018.
- Associated Press•7 days ago
Abeona Therapeutics: 4Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 36 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•7 days ago
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year results, and to provide business highlights. “The diligent work conducted over the past nine months at our GMP manufacturing facility puts us on track to initiate the pivotal VITAL™ study evaluating EB-101, our gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, in mid-2019.
- Simply Wall St.•last month
What Investors Should Know About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) Financial Strength
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Zero-debt allows substantial financial flexibility, especially for small-cap companies likeRead More...
- GlobeNewswire•last month
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference
NEW YORK and CLEVELAND, Feb. 22, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies.
- GlobeNewswire•last month
New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•last month
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced the appointment of João Siffert, M.D. as Chief Executive Officer (CEO), effective immediately. Dr. Siffert joined Abeona as Head of Research & Development (R&D) and Chief Medical Officer (CMO) in 2018, and has served as interim CEO since November of last year.
- ACCESSWIRE•2 months ago
The Unknown Biotech Play that Could Deliver 400% Returns, or Much More
The market for cell therapies of all kinds is exploding in size. Orgenesis Inc (ORGS) is making a name for itself as a top-notch provider of manufacturing to cell therapy drug developers. The company's revenue is growing consistently, and they recently achieved a key milestone under a 2018 investment agreement from a leading healthcare investment groups in the U.S., Great Point Partners.
- GlobeNewswire•2 months ago
Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™
NEW YORK and CLEVELAND, Jan. 31, 2019 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene.
- GlobeNewswire•2 months ago
Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.
- Simply Wall St.•3 months ago
How Should Investors Feel About Abeona Therapeutics Inc.’s (NASDAQ:ABEO) CEO Pay?
Tim Miller has been the CEO of Abeona Therapeutics Inc. (NASDAQ:ABEO) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
- Insider Monkey•3 months ago
Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
“Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]
- Zacks•3 months ago
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Zacks•3 months ago
Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- Zacks•4 months ago
Moving Average Crossover Alert: Abeona Therapeutics
Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- GlobeNewswire•4 months ago
Abeona Therapeutics to Host R&D Day on December 6, 2018
NEW YORK and CLEVELAND, Nov. 29, 2018 -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and.
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Abeona Therapeutics Announces CEO Transition
Abeona Therapeutics Inc. (ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the immediate termination of its Chief Executive Officer, Dr. Carsten Thiel due to personal misconduct that violated the Company’s Code of Business Conduct and Ethics.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
Q3 2018 Abeona Therapeutics Inc Earnings Call
- Zacks•4 months ago
Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Abeona Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the Dallas-based company said it had a loss of 34 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•4 months ago
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage.
